Lupus Erythematosus Clinical Trial
Official title:
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus (SLE) is the most common systemic autoimmune disease. The
clinical manifestations are severe and affect multiple target organs such as the kidney,
central nervous system, skin, heart and joints. Despite the progress made in the therapeutic
approach with new immunosuppressive regimens, morbi-mortality is still high. Therefore, it's
important to identify new biomarkers to help clinicians to predict severity and evolution of
the disease for better adaptation of treatments and try to improve the prognosis.
RAGE (Receptor for Advanced Glycation Endproducts) :
RAGE (Receptor for Advanced Glycation Endproducts) is an ubiquitous membrane receptor,
involved in development of many diseases such as diabetes, chronic renal failure but also in
vascular remodelling, inflammatory, infectious deseases and cancer. RAGE regulates a number
of crucial cell processes like inflammation, and tissue and cellular homeostasis.
RAGE is able to bind not only the advanced glycation end products (AGEs) such as
pentosidine, carboxymethyllysine (CML), methyl-glyoxal-hydroimidazolone-1 (MG- H1), but also
other ligands such as HMGB1 (high mobility group box1), and S100A8/A9 proteins which have
been correlated in recent studies to the activity index of SLE. The activation of RAGE leads
to a cascade of intracellular signaling and activation of the transcription factor NF-ΚB .
NF-ΚB enable the traduction of proinflammatory cytokines such as IL-6, IL-1α ,IFN-γ. In SLE,
these cytokines involved in perpetuation of inflammation and tissue damages including lupus
nephritis. Moreover, the activation of RAGE induces the expression of adhesion molecule such
as sICAM -1 and sVCAM -1 wich were recently involved in SLE vasculitis.
Soluble forms of RAGE, sRAGE and esRAGE :
RAGE is a proinflammatory membrane receptor. But RAGE also exists in soluble plasma forms,
esRAGE (secreted form) and sRAGE (a truncated form as cleaved by MMP9 and ADAM10 enzymes).
esRAGE and sRAGE have the same ligand-binding specificity as RAGE and may function as a
'decoy receptor' by binding pro-inflammatory ligands and preventing them from accessing cell
surface RAGE (Kierdorf and Fritz, 2013). Therefore, both soluble forms have an
anti-inflammatory action. Several studies have shown a decrease in circulating levels of
sRAGE in patients with Rheumatoid Arthritis, or Sjögren Syndrome compared with healthy
controls. However, the role of RAGE in SLE remains unknown.
RAGE and Systemic Lupus Erythematosus, recent advances :
Our team (Laboratory of Nephrology, CNRS UMR 7369, URCA) showed in a study in lupus RAGE
knockout mice (B6/ MRL-FAS lpr/J RAGE-/-) a strong involvement of RAGE in systemic
manifestations SLE. Recently, another report showed that sRAGE has an anti-inflammatory
effect on the lupus nephritis and could be a potent therapy in mice.
In humans, two studies show a correlation between the plasma level of sRAGE and lupus
phenotype ( Nienhuis et al. , 2008).
Working hypothesis :
Based on the results and those of the current studies, the investigators think that RAGE
axis and its soluble forms play a crucial role in the complex pathogenesis of SLE.
The investigators hypothesize that plasma levels sRAGE and esRAGE are a reflection of the
activity and the development of SLE in humans. Soluble forms of RAGE and ligands may be
novel biomarkers of SLE and sRAGE a potent therapeutic target.
Expected results :
The investigators expect a correlation between serum sRAGE, esRAGE and activity of SLE and
the presence of visceral involvement. Furthermore this study will allow us to analyze for
the first time in a lupus population, the correlation between soluble forms of RAGE (esRAGE,
sRAGE) and cytokines and molecules involved in lupus visceral involvement as IL-6, IL-1α,
IFN-γ, sICAM-1 and sVCAM-1.
Completion of our project, will allow better understanding of the role of RAGE and RAGE
ligand in SLE activity and will provide rationale for prospective study.
Future perspectives will include assessment of the risk-benefit for the use of anti-RAGE
strategies or recombinant sRAGE/esRAGE molecules as adjuvant treatment for SLE.
Study Design : the investigators designed an retrospective, analytic, transversal,
mulitcentric study. the investigators would like to use the serum and the clinical
information collected in "Lupus BioBanque du Rhin Supérieur" (LBBR UF 9882) to measure
soluble forms of RAGE, RAGE-ligands, cytokines, and sICAM and sVCAM. The investigators would
like to include 150 patients in this study.
Aim 1: The main objective of this study is to investigate the association between Systemic
Lupus Erythematosus (SLE) activity as measured by the SLEDAI score and serum concentrations
of sRAGE and esRAGE.
Aim 2 : The study of the correlation between the activity of other activity markers of SLE
and soluble forms of RAGE :
1. the concentration of RAGE ligands (AGEs like CML, pentosidine and MG-H1) and soluble
forms of RAGE (esRAGE, sRAGE)
2. the cytokine profile (IL-6, IL-1α, IFN-γ) and soluble forms of RAGE (esRAGE, sRAGE)
3. The concentrations of sICAM-1 and sVCAM-1 and soluble forms of RAGE (esRAGE, sRAGE)
Methods :
Inclusion criteria are :
- the LBBR inclusion criteria
- and Absence of immunomodulatory treatment,
- and preserved renal function (MDRD> 60ml/min).
Exclusion criteria are :
- renal failure defined by MDRD clearance < 60 mL/min/m2,
- or neoplasia,
- or diabetes,
- or other autoimmune disease,
- or current immunosuppressive treatments.
Data collection : About 500 μl of serum will be necessary for each patients to make all
measurements.
Mass spectrometry will be used for measurement of RAGE ligands (Advanced glycation end
products such as CML, pentosidine and MG-H1).
Commercially available ELISA kits will be used for measurement of sRAGE, esRAGE, sVCAM1.
Flow Cytometry will be used for measurement of cytokines (IL-6, IL-1a, IFN-y) and sICAM1.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Terminated |
NCT02080195 -
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT03562065 -
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
|
Phase 1/Phase 2 | |
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
Completed |
NCT04128579 -
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
|
Phase 1 | |
Recruiting |
NCT06161363 -
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
|
||
Completed |
NCT03421184 -
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
|
N/A | |
Completed |
NCT01686555 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT02747277 -
Analysis of B Cells From Autoimmune Individuals
|
||
Not yet recruiting |
NCT06426316 -
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
|
N/A | |
Recruiting |
NCT04213690 -
A Pilot Study to Explore the Role of Gut Flora in Lupus
|
||
Recruiting |
NCT03913754 -
Psycho-social Consequences of Systemic Lupus Erythematosus
|
||
Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
Completed |
NCT02455089 -
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus
|
N/A | |
Completed |
NCT04089930 -
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
|
||
Completed |
NCT05945784 -
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
|
||
Completed |
NCT03253666 -
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)
|